Evaxion's EVX-04 Vaccine Successfully Expressed in Human Cells for AML Treatment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 days ago
0mins
Source: Newsfilter
- Successful Vaccine Expression: Evaxion's EVX-04 vaccine has been successfully expressed and secreted in human cells, enabling immune recognition and activation, showcasing its potential as a novel treatment for acute myeloid leukemia (AML).
- Immune Response Induction: New data indicates that all endogenous retrovirus (ERV) antigens in EVX-04 drive specific immune responses in both mice and human cells, suggesting promising applications in cancer immunotherapy.
- Clinical Preparation Progress: Evaxion is actively executing preclinical activities while preparing regulatory filings for clinical testing, with data set to be presented at the European Hematology Association Congress on June 13, 2026, potentially enhancing treatment options for AML patients.
- Platform Advantage: The development of EVX-04 leverages the AI-Immunology™ platform, which utilizes artificial intelligence to identify and select antigen fragments with the highest potential for immune recognition, ensuring broad tumor coverage across different patients, highlighting its strategic significance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy EVAX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on EVAX
Wall Street analysts forecast EVAX stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 3.610
Low
10.00
Averages
12.33
High
16.00
Current: 3.610
Low
10.00
Averages
12.33
High
16.00
About EVAX
Evaxion A/S, formerly known as Evaxion Biotech A/S, is a Denmark-based clinical-stage biotechnology company, which specializes in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases. The Company decodes the human immune system to discover and develop immunotherapies to treat cancer and infectious diseases. Based on AI-immunology core technology, Evaxion is developing a pipeline of product candidates. In addition, Evaxion develops portfolio of vaccines to prevent bacterial and viral infections.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Evaxion Wins 2026 Prix Galien Award for AI-Immunology™
- Award Recognition: Evaxion A/S has been awarded the 2026 Prix Galien UK Award for Best Digital Health Solution for its AI-Immunology™ platform, highlighting its innovative capabilities and industry impact in vaccine development.
- Leadership Presentation: CEO Helen Tayton-Martin received the award at the ceremony held at the Natural History Museum in London, indicating the company's growing recognition within the scientific community and enhancing its market competitiveness.
- Continuous Innovation: The AI-Immunology™ platform utilizes artificial intelligence to decode the human immune system, driving the development of vaccines for cancer and infectious diseases, reflecting Evaxion's commitment to addressing unmet medical needs.
- Historical Achievements: This marks Evaxion's second Prix Galien award in less than a year, underscoring its significant contributions to biomedical science and human health, further solidifying its leadership position in the industry.
See More
Evaxion's EVX-04 Vaccine Shows Promise Against AML in Preclinical Findings
- Immune Response Activation: Evaxion's EVX-04 vaccine successfully triggers specific immune responses against acute myeloid leukemia (AML) in both mouse and human immune cell assays, demonstrating its potential as a new treatment approach for a cancer with poor long-term outcomes.
- Consistent Antigen Expression: The study shows that EVX-04 is correctly transcribed, translated, and secreted in human cells, ensuring that the immune system can recognize the vaccine antigens, thereby enhancing immune responses against AML and addressing the urgent need for new therapies.
- AI-Driven Antigen Selection: EVX-04 utilizes Evaxion's AI-Immunology platform to identify 16 tumor-specific antigens from the
See More
Evaxion's EVX-04 Vaccine Successfully Expressed in Human Cells for AML Treatment
- Successful Vaccine Expression: Evaxion's EVX-04 vaccine has been successfully expressed and secreted in human cells, enabling immune recognition and activation, showcasing its potential as a novel treatment for acute myeloid leukemia (AML).
- Immune Response Induction: New data indicates that all endogenous retrovirus (ERV) antigens in EVX-04 drive specific immune responses in both mice and human cells, suggesting promising applications in cancer immunotherapy.
- Clinical Preparation Progress: Evaxion is actively executing preclinical activities while preparing regulatory filings for clinical testing, with data set to be presented at the European Hematology Association Congress on June 13, 2026, potentially enhancing treatment options for AML patients.
- Platform Advantage: The development of EVX-04 leverages the AI-Immunology™ platform, which utilizes artificial intelligence to identify and select antigen fragments with the highest potential for immune recognition, ensuring broad tumor coverage across different patients, highlighting its strategic significance.
See More
Evaxion (EVAX) Q1 2026 Earnings Transcript
See More
Evaxion Biotech Reports Q1 2026 Financial Results
- Financial Performance: Evaxion Biotech reported a Q1 2026 GAAP EPS of -$0.01, indicating challenges in profitability, particularly with a significant drop in financial income compared to the same period last year.
- Decline in Financial Income: The financial income for Q1 2026 was $0.3 million, a stark decrease from $2.4 million in the prior year, primarily due to the remeasurement of derivative liabilities from the January 2025 public offering, reflecting the impact of market volatility on the company.
- Cash Flow Status: As of March 31, 2026, the company's cash and cash equivalents stood at $18.4 million, down from $23.2 million as of December 31, 2025, confirming the company's liquidity runway until the second half of 2027.
- Equity Changes: Total equity amounted to $13.2 million as of March 31, 2026, a decrease from $17.0 million as of December 31, 2025, indicating the impact of the net results from the first quarter on the company's financial health.
See More
Evaxion Reports Promising Phase 2 Trial Results for Personalized Cancer Vaccine EVX-01
- Clinical Trial Success Rate: Evaxion A/S's personalized cancer vaccine EVX-01 achieved an impressive 86% success rate in triggering tumor-specific immune responses during its Phase 2 trial for advanced melanoma, indicating the therapy's efficacy and potential.
- Durable Immune Responses: The two-year analysis confirmed that EVX-01 generated durable immune responses, including robust de novo T-cell activity, which may enhance tumor-killing potential, thereby providing better treatment options for patients.
- AI Platform Application: Evaxion's proprietary AI-Immunology platform played a crucial role in the precise selection of vaccine targets with unprecedented accuracy, with Chief Scientific Officer Bigitte Rønø emphasizing that these findings validate the platform's powerful potential in developing transformational cancer treatments.
- Technology Scalability: Evaxion reported progress in applying its AI-Immunology platform to glioblastoma, with preclinical findings demonstrating the successful design of personalized vaccines targeting glioblastoma, highlighting the technology's scalability beyond melanoma and its significant clinical implications.
See More
Evaxion Wins 2026 Prix Galien Award for AI-Immunology™
- Award Recognition: Evaxion A/S has been awarded the 2026 Prix Galien UK Award for Best Digital Health Solution for its AI-Immunology™ platform, highlighting its innovative capabilities and industry impact in vaccine development.
- Leadership Presentation: CEO Helen Tayton-Martin received the award at the ceremony held at the Natural History Museum in London, indicating the company's growing recognition within the scientific community and enhancing its market competitiveness.
- Continuous Innovation: The AI-Immunology™ platform utilizes artificial intelligence to decode the human immune system, driving the development of vaccines for cancer and infectious diseases, reflecting Evaxion's commitment to addressing unmet medical needs.
- Historical Achievements: This marks Evaxion's second Prix Galien award in less than a year, underscoring its significant contributions to biomedical science and human health, further solidifying its leadership position in the industry.
See More
Evaxion's EVX-04 Vaccine Shows Promise Against AML in Preclinical Findings
- Immune Response Activation: Evaxion's EVX-04 vaccine successfully triggers specific immune responses against acute myeloid leukemia (AML) in both mouse and human immune cell assays, demonstrating its potential as a new treatment approach for a cancer with poor long-term outcomes.
- Consistent Antigen Expression: The study shows that EVX-04 is correctly transcribed, translated, and secreted in human cells, ensuring that the immune system can recognize the vaccine antigens, thereby enhancing immune responses against AML and addressing the urgent need for new therapies.
- AI-Driven Antigen Selection: EVX-04 utilizes Evaxion's AI-Immunology platform to identify 16 tumor-specific antigens from the
See More
Evaxion's EVX-04 Vaccine Successfully Expressed in Human Cells for AML Treatment
- Successful Vaccine Expression: Evaxion's EVX-04 vaccine has been successfully expressed and secreted in human cells, enabling immune recognition and activation, showcasing its potential as a novel treatment for acute myeloid leukemia (AML).
- Immune Response Induction: New data indicates that all endogenous retrovirus (ERV) antigens in EVX-04 drive specific immune responses in both mice and human cells, suggesting promising applications in cancer immunotherapy.
- Clinical Preparation Progress: Evaxion is actively executing preclinical activities while preparing regulatory filings for clinical testing, with data set to be presented at the European Hematology Association Congress on June 13, 2026, potentially enhancing treatment options for AML patients.
- Platform Advantage: The development of EVX-04 leverages the AI-Immunology™ platform, which utilizes artificial intelligence to identify and select antigen fragments with the highest potential for immune recognition, ensuring broad tumor coverage across different patients, highlighting its strategic significance.
See More
Evaxion (EVAX) Q1 2026 Earnings Transcript
See More
Evaxion Biotech Reports Q1 2026 Financial Results
- Financial Performance: Evaxion Biotech reported a Q1 2026 GAAP EPS of -$0.01, indicating challenges in profitability, particularly with a significant drop in financial income compared to the same period last year.
- Decline in Financial Income: The financial income for Q1 2026 was $0.3 million, a stark decrease from $2.4 million in the prior year, primarily due to the remeasurement of derivative liabilities from the January 2025 public offering, reflecting the impact of market volatility on the company.
- Cash Flow Status: As of March 31, 2026, the company's cash and cash equivalents stood at $18.4 million, down from $23.2 million as of December 31, 2025, confirming the company's liquidity runway until the second half of 2027.
- Equity Changes: Total equity amounted to $13.2 million as of March 31, 2026, a decrease from $17.0 million as of December 31, 2025, indicating the impact of the net results from the first quarter on the company's financial health.
See More
Evaxion Reports Promising Phase 2 Trial Results for Personalized Cancer Vaccine EVX-01
- Clinical Trial Success Rate: Evaxion A/S's personalized cancer vaccine EVX-01 achieved an impressive 86% success rate in triggering tumor-specific immune responses during its Phase 2 trial for advanced melanoma, indicating the therapy's efficacy and potential.
- Durable Immune Responses: The two-year analysis confirmed that EVX-01 generated durable immune responses, including robust de novo T-cell activity, which may enhance tumor-killing potential, thereby providing better treatment options for patients.
- AI Platform Application: Evaxion's proprietary AI-Immunology platform played a crucial role in the precise selection of vaccine targets with unprecedented accuracy, with Chief Scientific Officer Bigitte Rønø emphasizing that these findings validate the platform's powerful potential in developing transformational cancer treatments.
- Technology Scalability: Evaxion reported progress in applying its AI-Immunology platform to glioblastoma, with preclinical findings demonstrating the successful design of personalized vaccines targeting glioblastoma, highlighting the technology's scalability beyond melanoma and its significant clinical implications.
See More
